List of Excipients in Branded Drug MOVANTIK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	MOVANTIK	naloxegol oxalate	0310-1969	CELLULOSE, MICROCRYSTALLINE	2028-09-16
AstraZeneca Pharmaceuticals LP	MOVANTIK	naloxegol oxalate	0310-1969	CROSCARMELLOSE SODIUM	2028-09-16
AstraZeneca Pharmaceuticals LP	MOVANTIK	naloxegol oxalate	0310-1969	FERRIC OXIDE RED	2028-09-16

MOVANTIK Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

MOVANTIK (naloxegol tablets) is an oral, once-daily treatment for opioid-induced constipation in adults with chronic non-cancer pain. Its excipient profile is conventional and low-complexity: mannitol, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and a film-coating system. The strongest commercial opportunities are therefore in generic supply, excipient cost reduction, differentiated oral products, manufacturing reliability, and adjacent opioid-induced constipation products rather than in a novel excipient platform.

Naloxegol is a PEGylated derivative of naloxol designed to limit central opioid antagonism while restoring gastrointestinal motility. MOVANTIK was approved by the FDA in September 2014 and is marketed as 12.5 mg and 25 mg film-coated tablets.[1]

What excipients are used in MOVANTIK tablets?

MOVANTIK uses standard tablet excipients that support direct compression or a closely related conventional solid-dose process.

Component	Function in MOVANTIK	Commercial relevance
Mannitol	Diluent and mouthfeel modifier	Provides bulk and a relatively clean sensory profile
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and process robustness
Croscarmellose sodium	Superdisintegrant	Promotes tablet breakup and dissolution
Povidone	Binder	Supports granule or tablet mechanical strength
Magnesium stearate	Lubricant	Controls ejection force and tooling performance
Hypromellose	Film-forming coating polymer	Protects the tablet and carries color
Titanium dioxide	Opacifier and pigment	Supports appearance and light protection
Talc	Coating aid and anti-tacking agent	Improves coating processability
Iron oxides	Colorants	Distinguish strengths and support product identification

The FDA-approved labeling identifies mannitol, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate in the tablet core. The coating contains hypromellose, titanium dioxide, talc, and iron oxide colorants.[1]

Why does MOVANTIK use mannitol?

Mannitol provides tablet mass and can improve mouthfeel compared with some alternative polyols. It also has relatively low hygroscopicity compared with certain other soluble fillers. For a naloxegol product, mannitol can support a compact tablet while limiting moisture-related processing problems.

A generic manufacturer could evaluate lactose, dibasic calcium phosphate, anhydrous dibasic calcium phosphate, or alternative grades of mannitol. The substitution must preserve dissolution, stability, tablet strength, impurity control, and bioequivalence.

What is the role of croscarmellose sodium?

Croscarmellose sodium is the principal rapid-disintegration component. Its performance depends on grade, particle size, degree of substitution, intra- versus extra-granular placement, and compression force.

A generic formulation that changes the superdisintegrant level or uses sodium starch glycolate or crospovidone could create a cost or supply advantage. The main technical risk is a shift in dissolution behavior. Naloxegol is a modified opioid antagonist with a delivery profile that must remain comparable to the reference product.

What formulation opportunities exist for MOVANTIK generics?

The most practical formulation opportunity is a bioequivalent immediate-release tablet with lower cost and equivalent or improved manufacturing robustness.

Excipient substitution

Potential development targets include:

1. Replacing branded or premium-grade mannitol with a qualified compendial grade.
2. Optimizing microcrystalline cellulose grade to improve flow and compression.
3. Reducing magnesium stearate sensitivity through controlled blending time.
4. Replacing or partially substituting croscarmellose sodium with crospovidone.
5. Using a lower-cost aqueous film-coating system.
6. Reducing coating weight while retaining appearance, mechanical protection, and stability.
7. Qualifying dual suppliers for each high-volume excipient.

The commercial value is greatest where the product is manufactured at high annual volume. Tablet excipients usually represent a small proportion of finished-product cost, but they affect line speed, rejection rates, yield, cleaning, and product-release timing. A formulation that reduces manufacturing variability can produce more value than one that merely lowers ingredient cost.

Direct compression versus granulation

The MOVANTIK excipient set is compatible with a conventional immediate-release tablet process. Direct compression could reduce equipment demand and processing steps, but the final choice depends on powder flow, blend uniformity, tablet weight, API loading, and segregation risk.

Wet granulation may improve content uniformity or tablet strength but introduces water, drying, and scale-up variables. A generic developer should assess whether naloxegol oxalate and the selected excipients maintain chemical stability during granulation and drying.

A robust commercial formulation should target:

• Low tablet-weight variability.
• Short blending and lubrication windows.
• Adequate hardness at high press speed.
• Rapid disintegration.
• Reference-product-matched dissolution.
• Low friability.
• Stable color and coating adhesion.
• Acceptable impurity growth under long-term and accelerated conditions.

What patents protect MOVANTIK and its formulation?

MOVANTIK is protected primarily by patents covering naloxegol, PEGylated opioid antagonists, compositions, and methods of treatment. The excipient list itself is not generally the principal source of exclusivity.

The Orange Book should be reviewed for the current patent listing and expiration data because listed patents and certifications can change through delisting, litigation, terminal disclaimers, patent-term adjustment, or regulatory updates.[2]

Protection category	Relevance to MOVANTIK	Generic impact
Naloxegol and PEGylated opioid antagonist composition patents	Protect the active pharmaceutical ingredient and chemical class	Can block or delay ANDA approval
Pharmaceutical composition patents	May cover dosage forms or compositions containing naloxegol	Relevant if claims require particular formulation characteristics
Method-of-use patents	Cover treatment of opioid-induced constipation or related indications	May require a section viii label carve-out
Manufacturing patents	May cover synthesis, PEGylation, purification, or intermediate control	Creates process-development and FTO issues
Excipient-specific claims	Potentially limited unless a particular composition or performance profile is claimed	Usually less important than API and use claims

Publicly associated MOVANTIK patent families include U.S. Patent Nos. 8,541,450 and 9,018,311, among other potentially relevant patents and continuations.[3,4] Exact enforceability and expiration require claim-level review of the current Orange Book listing, patent prosecution history, terminal disclaimers, and any litigation or settlement record.

Are the MOVANTIK excipients patent protected?

The named excipients are established pharmaceutical ingredients with extensive prior art. Mannitol, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, hypromellose, talc, titanium dioxide, and iron oxides are not, by themselves, likely to create a meaningful barrier to generic competition.

Risk can arise from a claim directed to:

• A specific excipient ratio.
• A defined dissolution profile.
• A narrow particle-size distribution.
• A particular coating architecture.
• A moisture-protection system.
• A manufacturing sequence.
• A combination of naloxegol with a specified excipient system.

A generic manufacturer should separate three questions: whether the formulation is outside the patent claims, whether the process avoids patented manufacturing steps, and whether the product label can be approved without infringing method-of-use claims.

When does MOVANTIK lose exclusivity?

MOVANTIK's practical loss of exclusivity depends on the interaction between FDA regulatory exclusivity, Orange Book patents, Paragraph IV litigation, and settlement terms.

The FDA approved naloxegol in 2014 through the new drug application pathway. The product's five-year new chemical entity exclusivity period would have ended in 2019, subject to statutory rules governing patent challenges and approval timing.[1,5]

The relevant commercial timeline is:

Event	Timing	Commercial effect
FDA approval of MOVANTIK	September 2014	Established the reference product
New chemical entity exclusivity	Approximately 2014-2019	Delayed ANDA submission for a period after approval
Patent challenge window	After statutory ANDA eligibility	Enabled Paragraph IV filings
Generic approval or launch	Dependent on ANDA status and patent resolution	Determines price erosion and share migration
Post-patent market	Dependent on surviving patents and settlements	Usually produces broader generic competition

There is no biosimilar pathway for MOVANTIK. Naloxegol is a synthetic small molecule, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application.

Which companies are challenging MOVANTIK?

Potential ANDA applicants can challenge MOVANTIK through Paragraph IV certifications asserting that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV certification can trigger patent litigation within the statutory period and may produce a 30-month stay of FDA approval under the Hatch-Waxman framework.[5]

Public sources have reported generic activity involving naloxegol, but the operative competitive picture depends on current FDA approval status, tentative approvals, launch dates, authorized-generic arrangements, and litigation outcomes. A commercial diligence review should prioritize:

• FDA Orange Book patent listings.
• FDA ANDA approval records.
• Paragraph IV notices and complaints.
• District court docket activity.
• Federal Circuit decisions.
• Settlement agreements and launch licenses.
• Current NDC and wholesale distribution activity.

The main competitive risk is not only the first generic entrant. Multiple approvals can follow quickly, producing sharp price compression, payer substitution, and loss of formulary preference.

What is the FDA regulatory status of MOVANTIK?

MOVANTIK is FDA-approved for the treatment of opioid-induced constipation in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation.[1]

The product is available in:

• 12.5 mg tablets.
• 25 mg tablets.

The label includes clinically important interaction and administration provisions. Strong CYP3A4 inhibitors are contraindicated, and dose adjustment is required with certain moderate CYP3A4 inhibitors and renal impairment. The product is administered on an empty stomach, at least one hour before the first meal of the day or two hours after the meal.[1]

These label restrictions create opportunities for differentiated products that improve adherence or reduce administration complexity, although a reformulated generic cannot freely change the approved label without a separate regulatory strategy.

What commercial opportunities exist in MOVANTIK excipients?

Lower-cost generic supply

The largest near-term opportunity is supply to generic manufacturers. Demand exists for qualified grades of mannitol, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and film-coating ingredients.

Suppliers can compete through:

• Dual-source qualification packages.
• Consistent particle-size specifications.
• Low-bioburden or low-endotoxin options where appropriate.
• Improved flow and compactability.
• Regulatory documentation for multiple jurisdictions.
• Stable supply contracts.
• Technical support for formulation transfer.

Excipient co-development

An excipient supplier can create value by developing a prequalified formulation platform rather than selling individual ingredients. A direct-compression blend containing mannitol, cellulose, and a superdisintegrant could shorten generic development and technology-transfer timelines.

The supplier must avoid implying that a co-developed formulation has regulatory approval. The value proposition is development efficiency, not automatic bioequivalence.

Coating-system opportunity

Film-coating materials offer a modest but practical opportunity. A coating supplier could provide:

• Lower coating weight.
• Faster drying.
• Improved adhesion.
• Reduced color variation.
• Better resistance to abrasion.
• Alternative color systems that meet jurisdiction-specific requirements.

Colorant strategy matters in global markets because titanium dioxide and iron oxide requirements can differ by jurisdiction and customer policy. A manufacturer may need color alternatives for Europe, the United States, and other regulated markets.

Reformulation and line-efficiency services

Contract development and manufacturing organizations can offer:

• Formulation reverse engineering.
• Comparative dissolution testing.
• Tablet compression optimization.
• Coating-process scale-up.
• Stability-package development.
• Excipient risk assessments.
• Post-approval change support.

The best commercial positioning is a complete immediate-release tablet platform for opioid-induced constipation, not a single raw-material sale.

How strong is the MOVANTIK patent estate?

The patent estate is stronger around the active molecule and therapeutic use than around the excipient system.

Strengths

• Naloxegol is a specialized PEGylated opioid antagonist.
• Chemical and process patents can create API-development barriers.
• Method-of-use claims may complicate full-label generic substitution.
• Manufacturing know-how may affect impurity control and cost.
• Orange Book patents can create approval timing risk even after NCE exclusivity ends.

Weaknesses

• The tablet excipients are conventional.
• Immediate-release tablet technology is mature.
• Generic manufacturers can usually design around individual excipient choices.
• The product has no biologic complexity.
• Multiple qualified suppliers exist for most excipient classes.

The highest-value diligence question is whether any surviving claims require a specific naloxegol composition or process that a generic cannot avoid. Excipient selection should be integrated into the FTO analysis, but it is unlikely to be the primary barrier.

What generic entry risks exist for MOVANTIK?

Generic entry could produce four commercial effects:

1. Lower pharmacy reimbursement and wholesale acquisition pricing.
2. Rapid payer substitution where therapeutic interchange is limited.
3. Reduced branded promotional support.
4. Pressure on authorized-generic or license-based strategies.

MOVANTIK competes with other prescription opioid-induced constipation therapies, including lubiprostone, linaclotide in relevant constipation markets, naldemedine, and methylnaltrexone. The closest pharmacologic comparator is likely Symproic (naldemedine), another peripherally acting mu-opioid receptor antagonist. Relistor (methylnaltrexone) is also relevant but has different dosage forms, indications, and administration considerations.

How does MOVANTIK compare with competing opioid-induced constipation drugs?

Product	Active ingredient	Class	Main differentiation
MOVANTIK	Naloxegol	PEGylated peripheral mu-opioid receptor antagonist	Once-daily oral tablet
Symproic	Naldemedine	Peripheral mu-opioid receptor antagonist	Once-daily oral tablet
Relistor	Methylnaltrexone	Peripheral mu-opioid receptor antagonist	Oral and injectable options
Amitiza	Lubiprostone	Chloride channel activator	Different mechanism and formulation
Trulance	Plecanatide	Guanylate cyclase-C agonist	Broader constipation positioning

MOVANTIK's commercial vulnerability is greatest where payers treat oral peripherally acting mu-opioid receptor antagonists as interchangeable. Its opportunity is strongest in patients and prescribers that value once-daily oral dosing, established clinical familiarity, and a conventional tablet.

What licensing deals affect MOVANTIK?

MOVANTIK originated from a collaboration involving AstraZeneca and Nektar Therapeutics. AstraZeneca later transferred or licensed commercial rights in certain markets, including U.S. rights associated with RedHill Biopharma's acquisition of MOVANTIK rights.[6]

Licensing history matters because the commercial counterparty may not be identical to the original patent owner, NDA holder, manufacturer, or current distributor. A diligence file should map:

• NDA ownership.
• Patent ownership.
• U.S. commercialization rights.
• Manufacturing rights.
• Authorized-generic rights.
• Royalty obligations.
• Settlement-based launch rights.
• Rights by geographic market.

The licensing structure can affect generic negotiations, supply agreements, and the economics of a potential authorized generic.

What manufacturing and geographic barriers affect MOVANTIK?

The API is more strategically important than the tablet excipients. Naloxegol manufacturing requires control of PEGylation chemistry, reaction impurities, molecular-weight distribution, residual solvents, and purification. These requirements can limit the number of reliable API suppliers.

For finished-dose manufacturers, the principal barriers are:

• API source qualification.
• Analytical method transfer.
• Impurity reference standards.
• Dissolution matching.
• Blend uniformity.
• Film-coating consistency.
• Stability under high-humidity conditions.
• Regulatory filings across jurisdictions.

Geographic opportunity is greatest in markets where opioid prescribing and chronic non-cancer pain treatment support OIC demand but generic availability remains limited. Excipient suppliers should prioritize manufacturers with multi-region registration capability because a single grade can support the U.S., European, Canadian, and selected emerging-market programs if documentation and compendial status align.

Key Takeaways

• MOVANTIK contains a conventional immediate-release tablet excipient system.
• The principal excipients are mannitol, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate, with a hypromellose-based film coat.
• Excipient-specific patent risk is likely lower than naloxegol composition, manufacturing, and method-of-use patent risk.
• The strongest commercial opportunity is a generic-ready excipient and formulation platform.
• Cost reduction should focus on manufacturing yield, press speed, coating efficiency, and supply reliability rather than raw-material price alone.
• MOVANTIK has no biosimilar risk because naloxegol is a synthetic small molecule.
• Paragraph IV activity, Orange Book listings, settlement terms, and current ANDA approvals determine the actual generic-entry timetable.
• API supply and PEGylation know-how are more significant barriers than tablet excipient availability.
• Competitive pressure comes primarily from generic naloxegol and other oral peripherally acting mu-opioid receptor antagonists.

FAQs About MOVANTIK Excipient and Patent Opportunities

Can a generic manufacturer use the same MOVANTIK excipients?

Yes. Generic manufacturers can generally use the same excipients if the formulation meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and dissolution. The manufacturer must still assess patent claims and manufacturing-process rights.

Is mannitol the most commercially important MOVANTIK excipient?

Mannitol is important as the primary diluent, but croscarmellose sodium and microcrystalline cellulose may have greater effects on dissolution, compression, and manufacturing performance. The commercial priority is the complete excipient system.

Could MOVANTIK be reformulated as a capsule?

A capsule or alternate dosage form would require a separate development and regulatory strategy. It would not automatically qualify as an ANDA-equivalent version of the reference tablet and could face different patent, labeling, stability, and bioequivalence requirements.

Does naloxegol require a special excipient to remain peripherally restricted?

The peripheral restriction is primarily a property of naloxegol's PEGylated molecular structure and pharmacology. Standard tablet excipients support delivery but do not independently create the peripheral opioid-antagonist profile.

What is the best licensing target around MOVANTIK?

The most attractive targets are qualified naloxegol API, generic-ready formulation technology, excipient premixes, coating systems, analytical methods, and manufacturing capacity. A standalone conventional excipient is less differentiated than a validated formulation and process package.

References

1. U.S. Food and Drug Administration. (2014). MOVANTIK (naloxegol) tablets prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Patent No. 8,541,450. (2013). Polyethylene glycol derivatives of opioid antagonists.
4. U.S. Patent No. 9,018,311. (2015). Methods and compositions comprising naloxegol.
5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process under the Hatch-Waxman Amendments.
6. RedHill Biopharma Ltd. (2019). Announcements concerning the acquisition and commercialization rights for MOVANTIK.